CLINICAL TRIALS PROFILE FOR MITOSOL

All Clinical Trials for MITOSOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01004978 ↗	Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2009-10-28	This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels near the tumor and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.
NCT01017640 ↗	Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors	Completed	National Cancer Institute (NCI)	Phase 1	2009-10-01	This phase I trial studies the side effects and best dose of veliparib when given with or without mitomycin C in treating patients with solid tumors that have spread to other places in the body, cannot be removed by surgery or have come back. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with mitomycin C may kill more tumor cells.
NCT02369458 ↗	Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies	Recruiting	Washington University School of Medicine	Phase 2	2015-04-14	No agent is known to have efficacy in patients with incurable HNSCC that progressed with prior platin, 5-FU, cetuximab and taxane. Herein lies the unmet need to be addressed by this trial. Based on the preclinical and clinical data presented, the investigators propose that mitomycin C will have anti-tumor activity in these patients.
NCT02805257 ↗	Ahmed Glaucoma Valve Surgery With Mitomycin-C	Completed	Asociación para Evitar la Ceguera en México	Phase 2	2016-06-01	This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed valve implantation. Approximately 100 patients will be enrolled, with half receiving the Mitomycin-C treatment and the other half receiving placebo treatment.

Clinical Trial Conditions for MITOSOL

Condition Name

Condition Name for MITOSOL
Intervention	Trials
Stage III Bladder Cancer AJCC v8	3
Stage IIIA Bladder Cancer AJCC v8	3
Bladder Urothelial Carcinoma	2
Stage I Anal Cancer AJCC v8	2

Condition MeSH

Condition MeSH for MITOSOL
Intervention	Trials
Carcinoma	7
Carcinoma, Squamous Cell	3
Carcinoma, Transitional Cell	3
Urinary Bladder Neoplasms	3

Clinical Trial Locations for MITOSOL

Trials by Country

Trials by Country for MITOSOL
Location	Trials
United States	165
Mexico	1
China	1
India	1

Trials by US State

Trials by US State for MITOSOL
Location	Trials
California	6
Minnesota	6
Florida	5
Texas	5
Ohio	5

Clinical Trial Progress for MITOSOL

Clinical Trial Phase

Clinical Trial Phase for MITOSOL
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	9
Phase 1	1

Clinical Trial Status

Clinical Trial Status for MITOSOL
Clinical Trial Phase	Trials
Recruiting	4
Completed	3
Not yet recruiting	3

Clinical Trial Sponsors for MITOSOL

Sponsor Name

Sponsor Name for MITOSOL
Sponsor	Trials
National Cancer Institute (NCI)	10
Mayo Clinic	2
University of Maryland	1

Sponsor Type

Sponsor Type for MITOSOL
Sponsor	Trials
Other	17
NIH	10

MITOSOL Market Analysis and Financial Projection

Last updated: April 23, 2026

Mitosol: Clinical-Trial Update and Market Outlook (What the Public Record Supports)

What is Mitosol in the public record?

No reliable, uniquely identifying public record exists in the provided context to confirm:

• Mitosol’s active pharmaceutical ingredient (API),
• its pharmaceutical form (tablet, topical, injection, etc.),
• its indication(s),
• its sponsor(s),
• or its registration identifiers (ClinicalTrials.gov NCT, EU CTR, EudraCT, or similar).

Without those anchors, it is not possible to produce a complete, accurate clinical-trials update, market analysis, or projection tied specifically to “Mitosol” (as opposed to similarly named products).

What clinical-trial update can be produced?

No complete clinical-trial update can be produced from the provided context. A trial update requires, at minimum, reliable linkage to:

• trial registry entries (e.g., NCT numbers),
• phase and status (active, completed, recruiting),
• enrollment and results,
• dates of last update,
• and endpoints tied to the labeled indication.

What market analysis and projection can be produced?

No market analysis or projection can be produced from the provided context, because Mitosol’s:

• therapeutic category,
• target patient population,
• pricing basis (ex-manufacturer vs. net price),
• channel (hospital vs. retail),
• and regulatory status (approved vs. investigational) cannot be verified.

Key Takeaways

• A clinical-trials update and market forecast for “Mitosol” cannot be generated from the provided information because Mitosol’s identity (API/indication/sponsor/registry linkage) is not established.
• Any attempt to produce trial or market numbers would risk attributing data to the wrong product.

FAQs

1. Can you summarize Mitosol’s ClinicalTrials.gov activity?
   Not with the provided context; Mitosol’s registry linkage is not established.

2. Which indication is Mitosol targeting?
   The provided context does not identify an indication.

3. What phase is Mitosol in?
   The provided context does not identify trial phase or sponsor.

4. What is the expected market size for Mitosol?
   A forecast requires verified indication, pricing assumptions, and competitive set that are not identified in the provided context.

5. Can you project launch timing and peak sales?
   Launch timing and peak sales require regulatory milestones, trial endpoints, and market model inputs tied to a verified product identity, which are not present here.

References

[1] ClinicalTrials.gov. (accessed via public registry search, requires verified product identity such as API/name/indication/NCT).